A Phase II Study of LN-145 Immunotherapy in People with Metastatic Non-Small-Cell Lung Cancer


Full Title

A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer


The purpose of this study is to assess the safety and effectiveness of the investigational immunotherapy LN-145 in patients with non-small cell lung cancer (NSCLC) that has metastasized despite prior treatment. LN-145 is called “autologous tumor infiltrating lymphocytes” (TIL) therapy. It activates white blood cells to attack the tumor.

TIL therapies are made in a laboratory from white blood cells called lymphocytes (T cells) that are collected from a patient’s tumor. Patients in this study will have T cells removed from their tumors to make the treatment and will receive intravenous chemotherapy (by vein) to prepare them for the treatment. They will then receive LN-145 intravenously.

Who Can Join

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients have metastatic NSCLC that has continued to grow despite immunotherapy and chemotherapy.
  • Patients should recover from the serious side effects of previous therapies before receiving LN-145.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Adam Schoenfeld at 646-608-4042.




Phase II (phase 2)


ClinicalTrials.gov ID